(1S)-1-(5-FLUORO-2-IODOPHENYL)ETHAN-1-OL
(S)-1-(5-fluoro-2-iodophenyl)ethan-1-ol
CAS: 1454847-96-1
Molecular Formula: C8H8FIO
(1S)-1-(5-FLUORO-2-IODOPHENYL)ETHAN-1-OL - Names and Identifiers
(1S)-1-(5-FLUORO-2-IODOPHENYL)ETHAN-1-OL - Physico-chemical Properties
| Molecular Formula | C8H8FIO |
| Molar Mass | 266.05 |
| Density | 1.812±0.06 g/cm3(Predicted) |
| Boling Point | 275.7±30.0 °C(Predicted) |
| pKa | 13.80±0.20(Predicted) |
| Use | Purposes 1, (S)-1-(2-iodo-5-fluorophenyl) ethanol is mainly used for pharmaceutical intermediates. 2. Key Intermediate of loratinib. Lorlatinib, a novel, reversible and potent small-molecule ALK and ROS1 inhibitor developed by Pfizer, has a strong inhibitory effect on known resistance mutations in ALK, therefore, it is known as the 3rd generation ALK inhibitor. Crizotinib is the world's first ALK mutation targeted drug for lung cancer. After treatment, ORR can reach more than 60% and PFS can reach 8-10 months, on August 26, 2011, it was approved by FDA for the treatment of ALK-positive advanced NSCLC. It is one of the fastest developing drugs in the history of cancer drugs and has rapidly become the standard drug for ALK-positive NSCLC patients. Safety Information |
(1S)-1-(5-FLUORO-2-IODOPHENYL)ETHAN-1-OL - Nature
| boiling point | 275.7±30.0 °C(Predicted) |
| density | 1.812±0.06 g/cm3(Predicted) |
| acidity coefficient (pKa) | 13.80±0.20(Predicted) |
Last Update：2024-04-10 22:29:15
(1S)-1-(5-FLUORO-2-IODOPHENYL)ETHAN-1-OL - Reference Information
| use | (S)-1-(2-iodo-5-fluorophenyl) ethanol is mainly used as a pharmaceutical intermediate. Lorantinib key intermediate. lorantinib (Lorlatinib) is a new, reversible and potent small molecule ALK and ROS1 inhibitor developed by Pfizer company. it has a strong inhibitory effect on the known drug resistance mutations of ALK, so it is known as the third generation ALK inhibitor. crizotinib is the world's first targeted drug for lung cancer with ALK mutation. after treatment, ORR can reach more than 60% and PFS can reach 8-10 months. on August 26, 2011, crizotinib was approved by FDA to treat ALK positive advanced NSCLC. it is one of the fastest developed drugs in the history of tumor drugs and has rapidly become the standard drug for ALK positive NSCLC patients. |
Last Update：2024-04-09 20:52:54
Supplier List
Multiple Specifications
Product Name: (alphaS)-5-Fluoro-2-iodo-alpha-methylbenzenemethanol Request for quotationCAS: 1454847-96-1
Tel: 0086-13605431940
Email: xuli678323@126.com
Mobile: +86-13605431940
QQ: 56860987
Wechat: 13605431940
WhatsApp: 13605431940
Multiple Specifications
Product Name: (alphaS)-5-Fluoro-2-iodo-alpha-methylbenzenemethanol Request for quotationCAS: 1454847-96-1
Tel: 0086-13605431940
Email: xuli678323@126.com
Mobile: +86-13605431940
QQ: 56860987
Wechat: 13605431940
WhatsApp: 13605431940
View History